Frank M. Balis

16.4k total citations · 1 hit paper
313 papers, 12.4k citations indexed

About

Frank M. Balis is a scholar working on Oncology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Frank M. Balis has authored 313 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Oncology, 103 papers in Molecular Biology and 68 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Frank M. Balis's work include Acute Lymphoblastic Leukemia research (68 papers), Neuroblastoma Research and Treatments (47 papers) and Cancer therapeutics and mechanisms (45 papers). Frank M. Balis is often cited by papers focused on Acute Lymphoblastic Leukemia research (68 papers), Neuroblastoma Research and Treatments (47 papers) and Cancer therapeutics and mechanisms (45 papers). Frank M. Balis collaborates with scholars based in United States, Canada and Germany. Frank M. Balis's co-authors include David G. Poplack, Peter C. Adamson, Elizabeth Fox, Brigitte C. Widemann, Susan M. Blaney, Cynthia Lester McCully, Seth M. Steinberg, Stacey L. Berg, Gregory H. Reaman and Diane E. Cole and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Frank M. Balis

307 papers receiving 12.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

2013 477 citations Frank M. Balis, Brenda J. Weigel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank M. Balis United States	64	3.8k	3.6k	2.4k	2.1k	1.8k	313	12.4k
Peter C. Adamson United States	59	2.7k 0.7×	3.5k 1.0×	2.2k 1.0×	2.2k 1.1×	2.2k 1.2×	238	11.3k
David G. Poplack United States	57	3.5k 0.9×	2.5k 0.7×	2.0k 0.9×	947 0.5×	3.0k 1.6×	225	11.4k
Peter H. Wiernik United States	69	7.1k 1.8×	5.2k 1.4×	2.6k 1.1×	1.3k 0.6×	3.4k 1.8×	511	19.7k
Susan M. Blaney United States	63	3.3k 0.9×	5.0k 1.4×	3.0k 1.3×	2.8k 1.3×	1.3k 0.7×	267	11.4k
Joseph R. Bertino United States	75	8.6k 2.3×	10.2k 2.8×	2.4k 1.0×	744 0.4×	2.9k 1.6×	471	23.2k
Vincent T. DeVita United States	61	5.1k 1.3×	2.0k 0.5×	3.0k 1.3×	1.8k 0.9×	1.2k 0.6×	191	14.2k
James F. Holland United States	59	5.6k 1.5×	4.3k 1.2×	2.1k 0.9×	596 0.3×	1.6k 0.9×	400	15.6k
Giuseppe Leone Italy	63	2.6k 0.7×	4.4k 1.2×	863 0.4×	523 0.3×	1.4k 0.7×	604	16.2k
Emil Frei United States	64	7.3k 1.9×	3.1k 0.8×	3.4k 1.5×	861 0.4×	1.9k 1.0×	272	15.8k
Daniel E. Fürst United States	64	1.4k 0.4×	2.1k 0.6×	1.8k 0.8×	690 0.3×	1.1k 0.6×	258	22.1k

Countries citing papers authored by Frank M. Balis

Since Specialization

Citations

This map shows the geographic impact of Frank M. Balis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank M. Balis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank M. Balis more than expected).

Fields of papers citing papers by Frank M. Balis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank M. Balis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank M. Balis. The network helps show where Frank M. Balis may publish in the future.

Co-authorship network of co-authors of Frank M. Balis

This figure shows the co-authorship network connecting the top 25 collaborators of Frank M. Balis. A scholar is included among the top collaborators of Frank M. Balis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank M. Balis. Frank M. Balis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geller, James I., Michael V. Ortiz, David Walterhouse, et al.. (2025). Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor. Pediatric Blood & Cancer. 72(10). e31915–e31915.

Shulman, David S., Kieuhoa T. Vo, Frank M. Balis, et al.. (2025). A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Medicine. 14(23). e71417–e71417.

Hogarty, Michael D., David S. Ziegler, Andrea Franson, et al.. (2024). Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. British Journal of Cancer. 130(5). 788–797. 10 indexed citations

Balis, Frank M., et al.. (2021). Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates. PubMed. 10. 26–29. 1 indexed citations

Oved, Joseph H., et al.. (2019). Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma. DNA and Cell Biology. 38(10). 1143–1146.

Kraft, Ira L., Srivandana Akshintala, Haiyan Lei, et al.. (2017). Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research. 24(4). 753–765. 20 indexed citations

Gore, Lia, S. Percy Ivy, Frank M. Balis, et al.. (2017). Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group. Journal of Clinical Oncology. 35(33). 3781–3787. 50 indexed citations

Barakat, Lamia P., Lisa A. Schwartz, Anne F. Reilly, Janet A. Deatrick, & Frank M. Balis. (2014). A Qualitative Study of Phase III Cancer Clinical Trial Enrollment Decision-Making: Perspectives from Adolescents, Young Adults, Caregivers, and Providers. Journal of Adolescent and Young Adult Oncology. 3(1). 3–11. 47 indexed citations

Fox, Elizabeth, Brigitte C. Widemann, Meredith K. Chuk, et al.. (2013). Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Clinical Cancer Research. 19(15). 4239–4248. 110 indexed citations

10.

Widemann, Brigitte C., AeRang Kim, Elizabeth Fox, et al.. (2012). A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 18(21). 6011–6022. 90 indexed citations

11.

Herzog, Cynthia E., Tanya Trippett, Joseph F. Grippo, et al.. (2010). Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors. Clinical Cancer Research. 17(3). 611–619. 41 indexed citations

12.

Kelly, Ronan J., Deborah Draper, Clara C. Chen, et al.. (2010). A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. Clinical Cancer Research. 17(3). 569–580. 151 indexed citations

13.

Gillespie, Andrea, Eva Dombi, Anne Goodwin, et al.. (2009). Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology. 73(16). 1273–1279. 59 indexed citations

14.

Abraham, Jame, Maureen Edgerly, Richard H. Wilson, et al.. (2009). A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research. 15(10). 3574–3582. 93 indexed citations

15.

Meany, Holly J., Elizabeth Fox, A. Hagey, & Frank M. Balis. (2006). In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines. Cancer Research. 66. 1021–1022. 2 indexed citations

16.

Connor, Edward M., P. A. Pizzo, Frank M. Balis, et al.. (1994). Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. 5(1). 20–32. 25 indexed citations

17.

Adamson, Peter C., et al.. (1992). Dose-Dependent Pharmacokinetics of All-trans-Retinoic Acid. JNCI Journal of the National Cancer Institute. 84(17). 1332–1335. 32 indexed citations

18.

Smith, Malcolm A., Peter C. Adamson, Frank M. Balis, et al.. (1992). Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer.. Journal of Clinical Oncology. 10(11). 1666–1673. 119 indexed citations

19.

Kelley, James A., Charles L. Litterst, David T. Vistica, et al.. (1987). The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.. Drug Metabolism and Disposition. 15(5). 595–601. 71 indexed citations

20.

Balis, Frank M., et al.. (1986). The Influence of Route of Administration on the Hepatic Uptake of Methotrexate. PubMed. 3(4). 239–242. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact